Antiarrhythmic therapies for the prevention of sudden cardiac death

Drugs

Volumn 54, Issue 2, 1997, Pages 235-252

  McAlister, Finlay A ^a   Teo, Koon K ^b,c  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; SOTALOL;

ACUTE HEART INFARCTION; AUTOMATIC CARDIOVERSION; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; CORONARY ARTERY BYPASS SURGERY; DEFIBRILLATOR; DRUG USE; HEART ARREST; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HIGH RISK PATIENT; HUMAN; PROPHYLAXIS; REVIEW; RISK; SECONDARY PREVENTION; SUDDEN DEATH;

EID: 0030750292     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199754020-00003     Document Type: Review

References (115)

1. Yusuf S, Venkatesh G, Teo KK. Critical review of the approaches to the prevention of sudden death. Am J Cardiol 1993; 72: 51-8F
2. Kannel WB, McGee DL, Schatzkin A. An epidemiologic perspective of sudden death: 26 year followup in the Framingham study. Drugs 1984; 28 Suppl. 1: 1-16
3. Thomas AC, Knapman PA, Krikler DM, et al. Community study of the causes of 'natural ' sudden death. BMJ 1988; 297: 1453-6
4. Schaffer WA, Cobb LA. Recurrent ventricular fibrillation and modes of death in survivors of out-of-hospital ventricular fibrillation. N Engl J Med 1975; 293: 259-62
5. Volpi A, Maggioni AP, Francozi MG, et al. Ventricular fibrilla-tion complicating myocardial infarction. N Engl J Med 1988; 318: 382-3
6. Luu M, Stevenson WG, Stevenson LW, et al. Diverse mechanisms of unexpected cardiac arrest in advanced heart failure. Circulation 1989; 80: 1675-80
7. Bigger Jr JT, Fleiss JL, Kleiger R, et al. The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction. Circulation 1984; 69: 250-8
8. Moss AJ. Clinical significance of ventricular arrhythmias in patients with and without coronary artery disease. Prog Cardiovasc Dis 1980; 23: 33-52
9. Coronary Drug Project Research Group. Prognostic significance of premature heats following myocardial infarction. JAMA 1973; 226: 1116-24
10. Ruberman W, Wernblatt M, Goldberg JD, et al. Ventricular premature heats and mortality after myocardial infarction. N Engl J Med 1977; 297: 750-7
11. Bikkina M, Larson MG, Levy D. Prognostic implications of asymptomatic ventricular arrhythmias: the Framingham Heart Study. Ann Intern Med 1992; 117: 990-6
12. Rahkin SW, Mathewson FA, Tatc RB. Relationship of ventricular ectopy in men without apparent heart disease to occurrence of ischemic heart disease and sudden death. Am Heart J 1981; 101: 135-42
13. Chiang RN, Perlman LV, Ostrander Jr LD, et al. Relationship of premature systoles to coronary heart disease and sudden death in the Tecumseh epidemiologic study. Ann Intern Med 1969; 70: 1159-69
14. Echt DS, Liehson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: the Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991; 324: 781-8
15. Cardiac Arrhythmia Suppression Trial II Investigators. Effect of antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992; 327: 227-33
16. Yusuf S, Teo KK. Approaches to prevention of sudden death: need for fundamental reevaluation. J Cardiovasc Electrophysiol 1991; 2 Suppl.: S233-9
17. Nattel S, Waters D. What is an antiarrhythmic drug? From clinical trials to fundamental concepts. Am J Cardiol 1990; 66: 96-9
18. Davies MJ. Pathological view of sudden cardiac death. Br Heart J 1981; 45: 88-96
19. Teo KK. Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. JAMA 1993; 270: 1589-95
20. Yusuf S, Peto R, Lewis J, Collins R, Sleight P Beta blockade during and after myocardial infarction: an overview of randomized trials. Prog Cardiovasc Dis 1985; 27: 335-71
21. Held PH, Yusuf S, Furhcrg CD. Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. BMJ 1989; 299: 1187-92
22. Britton M Diagnostic errors discovered at autopsy. Acta Med Scand l974; 196: 203-10
23. Gottlieb SS. Dead is dead - artificial definitions are no substitute. Lancet 1997; 349: 662-3
24. Pratt CM, Greenway PS, Schoenfeld MH, et al. Exploration of the precision of classifying sudden cardiac death: implications for the interpretation of clinical trials. Circulation 1996; 93: 519-24
25. Obiasmanno D, Friedmann E, Brooks MM, et al. Adherence and arrhythmic mortality in the cardiac arrhythmia suppression trial (CAST). Ann Epidemiol 1996; 6 (2): 93-101
26. Greenherg HM, Dwyer EM, Hochman JS, et al. Interaction of ischemia and encainide/flecainide treatment - a proposed mechanism for the increased mortality in CAST I. Br Heart J 1995; 74 (6): 631-5
27. Akiyama T, Pawitan Y, Greenberg H, et al. Increased risk of death and cardiac arrest from encainide and flecainide in patients after non-Q-wave acute myocardial infarction in the Cardiac Arrhythmia Suppression Trial. Am J Cardiol 1991; 68: 1551-5
28. Digitalis Investigation Group. Rationale, design, implementation and baseline characteristics of patients in the DIG trial: a large, simple long-term trial to evaluate the effect of digitalis on mortality in heart failure. Controlled Clin Trials 1996; 17: 77-97
29. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302
30. Bernsten RF, Rasmussen K. Lidocaine to prevent ventricular fibrillation in the prehospital phase of suspected acute myocardial infarction: the North Norwegian Lidocaine Intervention Trial. Am Heart J 1992; 124: 1478-83
31. Bertini G, Giglioli C, Rostagno C, et al. Early out-of-hospital lidocaine administration decreases the incidence of primary ventricular fibrillation in acute myocardial infarction. J Emerg Med 1993; 11: 667-72
32. MacMahon S, Collins R, Peto R, et al. Effects of prophylactic lidocaine in suspected acute myocardial infarction: an overview of results from the randomized, controlled trials. JAMA 1988; 260: 1910-6
33. Hine LK, Laird NM, Hewitt P, et al. Meta-analysis of empirical long-term antiarrhythmic therapy after myocardial infarction. JAMA 1989; 262: 3037-40
34. DeSilva RA, Hennekens CH, Lown B, et al. Lignocaine prophylaxis in acute myocardial infarction: an evaluation of randomized trials. Lancet 1981; II: 855-8
35. Navarro-Lopez F, Cosin J, Marrugat J, et al. Comparison of the effects of amiodarone versus metoprolol on the frequency of ventricular arrhythmias and on mortality after acute myocardial infarction. Am J Cardiol 1993; 72: 1243-8
36. Anastasiou-Nana MI, Gilbert EM, Miller RH, et al. Usefulness of d.l-sotalol for suppression of chronic ventricular arrhythmias. Am J Cardiol 1991; 67: 511-6
37. Kehoe R, Zheullin T, Dunnington C, Safety and efficacy of sotalol in patients with drug-refractory sustained ventricular tachyarrhythmias. Am J Cardiol 1990; 65: 58-64A
38. Ruder MA, Ellis T, Lebsack C, et al. Clinical experience with sotalol in patients with drug-refractory ventricular arrhythmias. J Am Coll Cardiol 1989; 13: 145-52
39. Singh SN, Cohen A, Chen YW, et al. Sotalol for refractory sustained ventricular tachycardia and nonfatal cardiac arrest. Am J Cardiol 1988; 62: 399-402
40. Anderson J. Effectiveness of sotalol for therapy of complex ventricular arrhythmias and comparisons with placebo and class I antiarrhythmic drugs. Am J Cardiol 1990; 65: 37-42A
41. Fitton A, Sorkin EM. Sotalol: an updated review of its pharmacological properties and therapeutic use in cardiac arrhythmias. Drugs 1993; 46: 678-719
42. Julian O, Jackson F, Szekely P, et al. A controlled trial of sotalol for one year after myocardial infarction. Circulation 1983; 67: 61-2
43. Waldo AL, Camm AJ, de Ruyter H, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 1996; 348: 7-12
44. Katritsis D, Camm AJ. Amiodarone in long term prophylaxis. Drugs 1991; 41 Suppl. 2: 54-66
45. Levine JH, Massumi A, Scheinman MM, et al. Intravenous amiodarone for recurrent sustained hypotensive ventricular tachyarrhythmias. J Am Coll Cardiol 1996; 27 (1): 67-75
46. Hockings BEF, George T, Mahrous F, et al. Effectiveness of amiodarone on ventricular arrhythmias during and after acute myocardial infarction. Am J Cardiol 1987; 60: 967-70
47. Burhart F, Pfisterer M, Kiowski W, et al. Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS). J Am Coll Cardiol 1990; 16: 1711- 8
48. Cairns JA, Connolly SJ, Gent M, et al. Post-myocardial infarction mortality in patients with ventricular premature depolarizations: Canadian amiodarone myocardial infarction arrhyihmia trial pilot study. Circulation 1991; 84: 550-7
49. Cosin J, de Luna AB, Navarro F, et al. Spanish Trial on Sudden Death: follow-up of 382 patients [abstract]. Circulation 1991; 84 Suppl. II: 348
50. Ceremuzynski L, Kleczar E, Krzeminska-Pakula M, et al. Effect of amiodarone on mortality after myocardial infarction: a double-blind, placebo-controlled, pilot study. J Am Coll Cardiol 1992; 20: 1056-62
51. Nicklas JM, McKenna WJ, Stewart RA, et al. Prospective, double-blind, placebo-controlled trial of low-dose amiodarone in patients with severe heart failure and asymptomatic frequent ventricular ectopy. Am Heart J 1991; 122: 1016-21
52. Hamer AWF, Arkles LB, Johns JA. Beneficial effects of low dose amiodarone in patients with congestive cardiac failure: a placebo-controlled trial. J Am Coll Cardiol 1989; 14: 1768-74
53. Garguichevich JJ, Ramos JL, Gambarte A, et al. Effect of amiodarone therapy on mortality in patients with left ventricular dysfunction and asymptomalie complex ventricular arrhythmias: Argentine pilot study of sudden death and amiodarone (EPAMSA). Am Heart J 1945; 130: 494-500
54. CASCADE Investigators. Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE study ). Am J Cardiol 1993; 72: 280-7
55. Doval HC, Nul DR. Grancclli HO. et al. Randomised trial of low-dose amiodarone in severe congestive heart failure. Lancet 1994; 344: 493-8
56. Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 1995; 333 77-82
57. Julian DG, Camm AJ, Frangin G, et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 1997; 349: 667-74
58. Cairns JA, Connolly SJ, Roberts R, et al. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Lancet 1997; 349: 675-82
59. ISIS-4 Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myoeardial infarction. Lancet 1995; 345: 669-82
60. Teo KK, Yusuf S, Collins R, Held PH. Effect of intravenous magnesium in suspected acute myocardial infarction: overview of randomized trials. BMJ 1991; 303: 1499-503
61. Woods KL, Fletcher S, Roffe C, et al. Intravenous magnesium sulphate in suspected acute myocardial infarction: results of the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). Lancet 1992; 339: 1553-8
62. Egger M, Davey Smith G. Misleading meta-analysis: lessons from 'an effective, safe, simple' intervention that wasn't. BMJ 1995; 310: 752-4
63. Yusuf S, Wittes J, Probstfield J, et al. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA 1991; 266: 93-8
64. Herre JM, Sauve MJ, Malone P, et al. Long-term results of amiodarone therapy in patients with recurrent sustained ventricular tachycardia or ventricular fibrillation. J Am Coll Cardiol 1989; 13: 442-9
65. Weinberg BA, Miles WM, Klein LS, et al. Five year follow-up of 589 patients treated with amiodarone. Am Heart J 1993; 125: 109-20
66. Dusman RE, Stanton MS, Miles WM, et al. Clinical features of amiodarone-induced pulmonary toxicity. Circulation 1991; 82: 51-9
67. Rengo F, Carhonin P, Pahor M, et al. A controlled trial of verapamil in patients after acute myocardial infarction: results of the Calcium Antagonist Reinfarction Italian Study (CRIS). Am J Cardiol 1996; 77: 365-9
68. Mazur NA, Pavlova TS, Vasil'eva NN, et al. The comparative efficacy of verapamil, nifedipine and propranolol in patients with IHD and an enhanced risk of a fatal outcome [in Russian, with English summary]. Ter Arkh 1994; 66: 26-30
69. Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92: 1326-31
70. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995; 274: 620-5
71. Pahor M, Guralnik JM, Corti MC, et al. Long-term survival and use of antihypertensive medications in older persons. J Am Geriatr Soc 1995; 43: 1191-7
72. Borhani NO, Mercuri M, Borhani PA, et al. Final outcome results of the Multicentcr Isradipine Diuretic Atherosclerosis Study (MIDAS): a randomized controlled trial. JAMA 1996; 276: 785-91
73. Packer M, O'Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996; 335: 1107-14
74. Boden WE, Scheldewaert R, Walters EG, et al. Design of a placebo-controlled clinical trial of long-acting diltiazem and aspirin versus aspirin alone in patients receiving thrombolysis with a first acute myocardial infarction. Am J Cardiol 1995; 75: 1120-3
75. Yusuf S, Held P, Furberg C. Update of effects of calcium antagonists in myocardial infarction or angina in light of the Second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies. Am J Cardiol 1991; 67: 1295-7
76. Yusuf S. Verapamil following uncomplicated myocardial infarction: promising, but not proven. Am J Cardiol 1996; 77: 421-2
77. Myocardial Infarction Study Group. Secondary prevention of ischemic heart disease: a long term controlled lidoflazine study. Acta Cardiol 1979; 34 Suppl. 24: 7-46
78. Friedman LM, Byington RP, Capone RJ, et al. Effect of propranolol in patients with myocardial infarction and ventricular arrhythmias. J Am Coll Cardiol 1986; 7: 1-8
79. Daubert AP, Kim CH. Nonsustained ventricular tachycardia: current evaluation and management. Annals Noninvasive Electrocardiology 1997; 2: 79-91
80. ESVEM Investigators. A randomized comparison of electrophysiologic study to electrocardiographic monitoring for prediction of antiarrhythmic drug efficacy in patients with ventricular tachyarrhythmias. N Engl J Med 1993; 329: 445-51
81. Steinbeck G, Greene HL. Management of patients with life-threatening sustained ventricular tachyarrhythmias - the role of guided antiarrhythmic drug therapy. Prog Cardiovasc Dis 1996; 38 (6): 419-28
82. Yusuf S, Zucker D, Peduzzi P, et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomized trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet 1994; 344: 563-70
83. Bouboulis N, Chan WK, Hilton CJ, et al. Nonischemic ventricular tachycardia - surgical or medical treatment. J Card Surg 1995; 10 (6): 644-51
84. Geha AS, Elefteriades JA, Hsu J, et al. Strategies in the surgical treatment of malignant ventricular arrhythmias: an 8-year experience. Ann Surg 1992; 216 (3): 309-16
85. Saksena S, Madan N, Lewis C. Implanted cardioverter-defibrillators are preferable to drugs as primary therapy in sustained ventricular tachyarrhythmias. Prog Cardiovasc Dis 1996; 38 (6): 445-54
86. Winkle RA, Mead RH, Ruder MA, et al. Long-term outcome with the automatic implantable cardioverter defibrillator. J Am Coll Cardiol 1989; 13: 1353-61
87. Tchou PJ, Kadri N, Anderson J, et al. Automatic implantable cardioverter defibrillators and survival of patients with left ventricular dysfunction and malignant ventricular arrhythmias. Ann Intern Med 1988; 109: 529-34
88. Crandall BG, Morris CD, Cutler JE, et al. The implantable cardioverter defibrillator in non-inducible sudden death survivors [abstract]. Circulation 1991; 84: 11-609
89. Pinski SL, Sgarhossa EB, Maloney JD, et al. Survival in patients declining implantable cardioverter defibrillators. Am J Cardiol 1991; 68: 800-1
90. Bocker D, Haverkamp W, Block M, et al. Comparison of d,lsotalol and implantable defibrillators for treatment of sustained ventricular tachycardia or fibrillation in patients with coronary artery disease Circulation 1996; 94 (2): 151-7
91. Sweeney MO, Ruskin JN, Garan H, et al Influence of the implantable cardioverter/defibrillator on sudden death and total mortality in patients evaluated for cardiac transplantation. Circulation 1995; 92 (11): 3273-81
92. Connolly S, Yusuf S. Evaluation of the implantable cardioverter defibrillator in survivors of sudden death: the need for randomized trials. Am J Cardiol 1992; 69: 959-62
93. Siebels J, Kuck KH. Implantable cardioverter defibrillator compared with antiarrhythmic drug treatment in cardiac arrest survivors (the Cardiac Arrest Study Hamburg) Am Heart J 1994; 127: 1139-44
94. Moss AJ, Hall J, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996; 335: 1933-40
95. Friedman PL, Stevenson WG. Unsustained ventricular tachycardia - to treat or not to treat. N Engl J Med 1996; 335: 1984-5
96. Yusuf S. Design of studies to critically evaluate if detection of asymptomatic ST- segment deviation (silent ischemia) is ot medical or public health importance. In: Singh BN. editor. Silent myocardial ischemia and angina: prevalence, prognostic and therapeutic significance New York: Pergamon Press. 1988; 206-19
97. Hunink MGM, Goldman L, Tosteson ANA, et al. The recent decline in mortality from coronary heart disease. 1980-1990: the effect of secular trends in risk factors and treatment. JAMA 1997; 277: 535-42
98. Lewis Jr HD, Davis JW, Archibald DG, et al. Protective effects of aspirin against myocardial infarction and death in men with unstable angina: results of a Veterans Administration co-operalive study. N Engl J Med 1983; 309: 396-403
99. ISIS-2 (Second International Study of Infarct Survival Collaborative Group). Randomized trial of intravenous strepto-kinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction. Lancet 1988; 11: 349-59
100. Anturane Reinfarction Trial Research Group. Sultinpyrazone in the prevention of sudden death after myocardial infarction. N Engl J Med 1480; 302: 250-6
101. Scandinavian Sunvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Studs (4S). Lancet 1994; 344: 1383-9
102. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on morbidity and mortality in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992; 327: 669-77
103. Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effects of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-8
104. Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995; 333: 1670-6
105. Ambrosioni E, Borghi C, Magnani B, et al. The effect of the angiotensin-convcrling-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995; 332: 80-5
106. Kleiger RE, Miller P, Bigger JT, et al. Multicenter Post Infarction Research Group: decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 1987; 59: 256-62
107. Takase B, Kurita A, Uehata A, et al. Prognostic importance of heart rate variability in patients with diabetes mellitus, congestive heart failure, and coronary artery disease [abstract]. Circulation 1990; 80: 111-354
108. Schwartz PJ, Motolese M, Pollavini G, et al. Surgical and pharmacological antiadrenergic interventions in the prevention of sudden death after a first myocardial infarction [abstract]. Circulation 1985; 72: III-355
109. O'Connor GT, Buring JE, Yusuf S, et al. Overview of randomized trials of physical rehabilitation following myocardial infarction. Circulation 1989; 80: 234-44
110. Dyckner T. Serum magnesium in acute myocardial infarction: relation to arrhythmias. Acta Med Scand 1980; 207: 59-66
111. Wester PO, Dyckner T. Intracellular electrolytes in cardiac failure. Acta Med Scand 1986; 707 Suppl.: 33-6
112. Karppanen H. Epidemiological studies on the relationship between magnesium intake and cardiovascular diseases. Artery 1981; 9: 190
113. Arsenian MA. Magnesium and cardiovascular disease. Prog Cardiovasc Dis 1993; 35: 271-310
114. Teo KK, McAlister FA, Montague TJ. Results of randomized clinical trials of magnesium - can a consensus be reached? Coron Artery Dis 1996; 7: 341-7
115. Clinical Quality Improvement Network (CQIN) Investigators. Mortality risk and patterns of practice in 4606 acute care patients with congestive heart failure: the relative importance of age, sex, and medical therapy. Arch Intern Med 1996; 156: 1669-73